MBD Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Suwon Gyeonggi-do South Korea

Primary Industry

Biotechnology

About

Based in Suwon-si, South Korea, and founded in 2015, MBD is a biotechnology company that uses 3D cell culture platform technology to develop drug efficacy and toxicity for anti-cancer drugs. In 2018, MBD developed a treatment platform for liver cancer patients in Singapore. In 2019, MBD's products such as ASFA Spotter and ASFA Scanner were approved by the FDA. The company's team of researchers and engineers have developed 3D cell cultivation platform for cell biology research and drug screening such as Cellvitro, ASFA Spotter, and ASFA Scanner. MBD uses 3D cell culture technology to extract cancer cell samples to develop anti-cancer treatments. The company plans to develop different types of medical devices for detecting ovarian cancer and breast cancer. The company has collaborated with research institutes to begin clinical trials for European patients.

Current Investors

Bokwang Venture Capital, E&Investment, G.N.TECH Venture Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals

Website

www.mbdbiotech.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.